Myristoyl Hexapeptide-23

1. Promotion of extracellular matrix (ECM) biosynthesis and collagen synthesis

Upon topical delivery, the Kpeptide peptide binds to cell surface receptors of dermal fibroblasts and epidermal keratinocytes, triggering intracellular signaling cascades that upregulate gene expression and protein production of type I and type III collagen, fibronectin and other ECM components. More intact ECM network reinforces dermal structural support, lifts skin firmness and elasticity, alleviates sagging induced by collagen loss, and fades fine lines and superficial wrinkles from early aging and photo‑damage.

2. Epidermal‑dermal junction reinforcement and barrier repair

It modulates keratinocyte behavior to strengthen epidermal integrity. Healthy keratinocyte turnover and basement membrane protein expression help restore the epidermal‑dermal connection. This stabilizes skin texture, reduces roughness and dullness caused by inflammation and UV exposure, and supports long‑term youthful skin appearance. This feature is particularly valuable for inflamed acne skin, where inflammatory insults often degrade collagen and accelerate premature aging.

3. Anti‑inflammatory anti‑aging synergy

By mitigating excessive inflammatory cytokine release, it lowers chronic low‑grade skin inflammation. Persistent inflammation drives matrix metalloproteinase (MMP) overexpression that breaks down collagen. The peptide indirectly reduces ECM degradation, slowing the progression of early aging and post‑inflammatory scarring and discoloration.

Molecular design phase

The molecule was rationally designed as a lipo‑signal peptide. The N‑terminal myristoyl group was introduced to solve the poor skin penetration limitation of ordinary hexapeptides. The peptide backbone was engineered to mimic endogenous skin repair signaling fragments. The dual biological profile was targeted: cationic structure for selective antibacterial activity against *Cutibacterium acnes, while the peptide sequence retains biomimetic signaling capacity to activate fibroblasts and keratinocytes. The raw material is manufactured via solid‑phase peptide synthesis with HPLC purity ≥95%.

In vitro cellular study stage

A series of in vitro cell assays were performed to validate its signal modulation on human dermal fibroblasts and epidermal keratinocytes:

1. Fibroblast signaling verification

When applied to cultured human dermal fibroblasts, myristoyl hexapeptide-23 acts as an extracellular messenger to activate downstream transcription pathways. Assays confirmed upregulated expression of collagen I, collagen III and fibronectin. The peptide signals fibroblasts to increase ECM secretion, which is the primary mechanism for dermal firming. Cell cytotoxicity tests demonstrated low cellular toxicity at working concentrations.

2. Keratinocyte signaling verification

In human keratinocyte culture models, the peptide modulates keratinocyte proliferation, differentiation and cytokine secretion profiles. It promotes proteins related to epidermal basement membrane and barrier function, and suppresses overproduction of pro‑inflammatory mediators. This signaling stabilizes epidermal homeostasis, reduces inflammation‑triggered matrix breakdown, and supports cross‑talk between epidermis and dermis.

3. Mechanism comparisonDistinct from retinoids or high‑concentration acids that directly stimulate cell turnover with high irritation risk,

this lipopeptide works through mild receptor‑mediated signal transduction. It does not cause drastic cell stress, which explains its good compatibility with sensitive inflamed acne skin.

Human clinical efficacy evaluation

A 12‑week human in‑use clinical test was carried out using formulations containing Kpeptide Myristoyl Hexapeptide‑23. Clinical outcomes showed statistically measurable improvements in skin elasticity, firmness and skin texture. The panel also exhibited reduced acne lesions and facial redness. The trial confirmed that under topical use, the peptide achieves both anti‑acne and early anti‑aging benefits on human skin. It is positioned as a cosmetic active for acne‑prone skin with early aging concerns.

2.4 Industrial and regulatory status

myristoyl hexapeptide-23 is classified as a cosmetic raw material, not a pharmaceutical agent. Its safety profile complies with cosmetic regulations in China, EU REACH and US TSCA. Solid‑phase synthesis has been scaled up for commercial supply. Current published research mainly covers in vitro cell tests and cosmetic human efficacy studies. There are no large‑scale clinical investigations for therapeutic drug indications.

1. Temperature control: Recommended transport temperature ≤25 °C. Avoid exposure to sunlight and heat sources. Long-distance ocean or air freight should prefer cool ambient conditions; cold chain is optional but recommended for high-volume shipments.

2. Moisture protection: Keep Kpeptide packages dry at all times. Prevent rain, water immersion and high-humidity warehouse transshipment. Do not open inner foil bags during transit.

3. Handling rule: Handle gently. Avoid heavy dropping, extrusion and package rupture. Stacking height is limited to prevent crushing outer cartons.

4. Compatible cargo: Separate from strong oxidants, strong acids and strong alkaline goods. Can be shipped together with general cosmetic raw materials.

Available transport modes

- Air freight: Acceptable as general cargo. Provide MSDS for airline declaration.

- Sea freight: General sea cargo. Recommended to select dry container; avoid container direct sun heating.

- Land freight (truck): General chemical cargo. Select covered truck; keep cargo away from cabin heating.

Transit documentation

Required documents: Commercial invoice, packing list, MSDS, COA (Certificate of Analysis. Some destinations may require cosmetic raw material declaration forms.

Storage after arrival

Upon receipt, transfer goods to dry warehouse at temperature ≤25°C, relative humidity <60%, away from light. Keep bags sealed until use. Shelf life remains valid under proper storage.

Risk contingency

If packaging is damaged during transit, isolate the package immediately to prevent moisture absorption of peptide powder. Inspect COA and sample testing before use if package integrity is compromised.